Skip to main content

and
  1. No Access

    Article

    Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

    Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we comp...

    Laurie E. McLouth, Yue Zheng, Stephanie Smith, F. Stephen Hodi in Quality of Life Research (2023)

  2. Article

    Open Access

    Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males

    We hypothesized that a gender difference in clinical response may exist to adjuvant CTLA4 blockade with ipilimumab versus high-dose IFNα (HDI). We investigated differences in candidate immune biomarkers in the...

    Mariam Saad, Sandra J. Lee, Aik Choon Tan in Journal of Translational Medicine (2022)

  3. Article

    Open Access

    Modeling the natural history of ductal carcinoma in situ based on population data

    The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the ...

    Sarocha Chootipongchaivat, Nicolien T. van Ravesteyn, **aoxue Li in Breast Cancer Research (2020)

  4. Article

    Open Access

    MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

    Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemot...

    Liza C. Villaruz, Grace Huang, Marjorie Romkes, John M. Kirkwood in Clinical Epigenetics (2015)

  5. Article

    Open Access

    HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners

    Previous studies suggest that active selection limits the number of HIV-1 variants acquired by a newly infected individual from the diverse variants circulating in the transmitting partner. We compared HIV-1 e...

    Victor Pena-Cruz, Behzad Etemad, Nikolaos Chatziandreou, Phyu Hninn Nyein in Retrovirology (2013)

  6. No Access

    Article

    An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection

    Gene silencing by small interfering RNAs (siRNAs) is involved in many biological processes. It has the potential to become an important form of therapy, but a major obstacle is the difficulty of delivering siR...

    Deborah Palliser, Dipanjan Chowdhury, Qing-Yin Wang, Sandra J. Lee in Nature (2006)